ArticleCancer medicine2024

Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.

Enver Aydilek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.